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So far four randomized studies, three of them double-blind and placebo-controlled, have
investigated the role of bismuth subsalicylate (BSS) in the treatment of travelers' diar-
rhea. When compared with placebo BSS significantly reduced the number of unformed
stools and increased the proportion of patients free of symptoms at the end of the trial.
In the two studies that compared BSS with loperamide, the latter agent brought signifi-
cantly faster relief. Diarrhea accompanied by dysenteric symptoms was influenced most
favorably by administration of systemic antimicrobial agents. In all four studies only mi-
nor adverse effects werenoted with BSSor the other active agents. One may include loper-
amide and a systemic antimicrobial agent in one's travel kit; however, loperamide should
not be used for dysentery, and the antimicrobial agent should not be used in uncompli-
cated cases. As an alternative, although it is less effective, BSS has the unique advantage
of being safe enough to use for all patients with travelers' diarrhea.
Each year 16million persons who travel from an in-
dustrialized country to a developing country are at
considerable risk of developing travelers' diarrhea
[1, 2]. These travelers have been discouraged from
taking any prophylactic medication [3], and ex-
perience shows that they are usually unable or un-
willing to maintain perfect vigilance with respect to
eating or drinking habits [4]. Instead of observing
the traditional rule - "boil it, cook it, peel it, or for-
get it" - travelers want to enjoy their freedom, in the
manner of Mark Twain, who once remarked, "Part
of the secret of success is to eat what you like and
let the food fight it out inside." Self-treatment of
travelers' diarrhea, therefore, remains an important
issue.
This report summarizes the four clinical trials that
have so far been carried out on the role of bismuth
subsalicylate (BSS) in (self-)treatment of travelers'
diarrhea.
Subjects and Methods
The first trial (trial 1) was conducted by DuPont et
al. [5]. Students originating from the United States
and in Latin America were studied between June
1975 and April 1976 while they were attending a
university in Cholula, Mexico (figure 1).Unless they
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were already taking antidiarrheal or antimicrobial
agents, students with three or more unformed stools
in the preceding 24 hours associated with one or sev-
eral symptoms of enteric infection were treated with
BSS or placebo (table 1)in this randomized double-
blind trial. Patients with more severe illness (as
reflected by five or more unformed stools per 24
hours) were given a double dose. In both treatment
groups, medication was taken for only 3~ hours.
All students collected stool samples, which wereana-
lyzed in a field laboratory.
In the second study (trial 2), again conducted by
the Houston group [6],adult students wererecruited
from volunteers working in seven Latin American
countries and from students from the United States
and Latin America who were attending courses in
Guadalajara, Mexico. Diarrhea, in this study, was
defined as four or more unformed stools associated
with one or more symptoms of enteric infection. Ex-
clusion criteria similar to those in trial 1 applied, but,
additionally, all subjects with dysentery or a tem-
perature of >102°P wereexcluded. In this non-blind,
randomized study, the subjects received either BSS
or loperamide for 2 days (table 1).Each subject kept
a daily record of symptoms and medication. Stools
were sent either to Houston or to the field labora-
tory in Guadalajara in three-vial fecal transport
systems.
The third study (trial 3) was a joint study by the
Houston group in Mexico and the Zurich group in
Banjul, The Gambia [7]. It was undertaken to com-
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Figure 1. Location of four trials of
the therapeutic efficacy of BSS in
travelers' diarrhea.
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pare etiologic agents in two widely different loca-
tions, to test two preservation kits for transpor-
tation of stool specimens from West Africa to
Houston, and to evaluate BSS with the use of vari-
ous disease-severity criteria for entrance into the
study (table 1). We will concentrate here on the lat-
ter aspect. A dose of 4.2 g of BSS or placebo was
givento the volunteers in a double-blind, randomized
manner. Whereas patients in Mexico were included
in the study only after they had voided at least three
unformed stools, those in West Africa could start
treatment immediately, conditions that mimick the
actual pattern of usage.
For the fourth study (trial 4), visitors to the Zurich
University Vaccination Center were invited to par-
ticipate on a voluntary basis in a study of self-
Table 1. Entrance criteria and regimens used in four trials of self-treatment of travelers' diarrhea.
Study, entrance criteria
Trial 1
~3 unformed stools/24 h
~5 unformed stools/24 h
Trial 2
~4 unformed stools/24 h, plus
other symptom(s)
Trial 3 (West Africa)
Onset of symptoms
Trial 3 (Mexico)
~3 unformed stools in an 8-hour
period or ~4 in 24 h, plus
other symptoms
Trial 4*
Onset of symptoms
Agent, dosage
BSS, 525 mg in 8 half-hourly doses
Placebo, same
BSS, 1,050 mg in 8 half-hourly doses
Placebo, same
BSS, 525 mg in 8 half-hourly doses
Loperamide, initial dose 4 mg, then 2 mg after
each unformed stool (~8 doses/24 h)
BSS, 1,050 mg in 4 hourly doses
Placebo, same
BSS, 525 mg in 8 half-hourly doses
Placebo, same
BSS, 525 mg in 8 half-hourly doses
Doxycycline, 100 mg twice daily
Loperamide, initial dose 4 mg, then 2 mg after
each unformed stool (~8 doses/24 h)
Mecillinam, 400 mg three times daily
Streptococcus faecium, 75 X 1()6 SF 68
TMP-SMZ, 160/800 mg twice daily
Placebo, various dosing periods
Dosage over
24 h
4.3 g
8.4 g
3.1-4.2 g
4-16 mg
4.2 g
4.2 g
4.2 g
200 mg
4-16 mg
1.2 g
225 x 1()6 SF 68
320-1,600 mg
No. of
participants
56
55
27
31
107
111
67
63
49
50
400
400
400
400
400
150
430
* Not all of the participants in trial 4 had diarrhea.
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Figure 2. Mean number of unformed stools after BSS
or placebo therapy in trial 1; n.s. = not significant.
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given only 4.2 g daily. A significance level of P <.05
was reached only in the group with diarrhea due to
enterotoxigenic Escherichia coli (ETEC) for the 4-
to 24-hour and 4- to 48-hour periods. In the other
etiologic groups the trend was less pronounced but
was favorable for BSS as well. Patients with shigel-
losis in the active treatment groups did not experience
a prolonged illness. Subjective relief of the symp-
toms of diarrhea, nausea, and abdominal pain within
24 hours of therapy was reported significantly more
often in the BSS group.
According to results from trial 2, loperamide re-
duced the number of unformed stools faster than
did BSS (figure 3). This benefit was most marked
during the first hours and the first day of illness. Sub-
jects whose condition did not improve with the test
medication could choose to take trimethoprim-
sulfamethoxazole (TMP-SMZ); ""250/0 in each treat-
ment group elected to do so. Analysis of the response
to therapy by etiologic agents showed that lopera-
mide reduced the number of unformed stools faster
for all etiologic categories during all assessed time
intervals. However, again, the significance level was
reached only within the first day.
In trial 3 the enteropathogens isolated were very
similar at both study sites (table 2), especially if we
consider that in West Africa two different vial kits
were used, which explains the higher rates of iso-
lation.
Compared with placebo, BSS in both West Africa
and Mexico reduced by 25% the time from initia-
tion of therapy to the last unformed stools and re-
Results
Trial 1 showed a significant decrease in stool fre-
quency in both the low-dose and the high-dose BSS
groups when compared with the placebo group for
the 4-to 24-hour surveillance period (figure 2). Dur-
ing the second day, a levelof significance was reached
only in the students who received the higher dose
of the active drug. One wonders whether the higher
dose of BSS offered faster relief; but, astonishingly,
upon initiation of therapy, the patients who received
placebo in the groups with severe illness also voided
fewer unformed stools than did their counterparts
in the moderately ill group.
BSS was similarly effective in the treatment of
travelers' diarrhea of various etiologic origin. Eight
students with shigellosis received 8.4 g of BSS daily,
while all other students in this separate analysis were
.treatment of travelers' diarrhea if they were going
to travel to Africa, Asia, or Latin America for 7-31
days and were 16-70 years of age [8].
The six active agents listed in table 1 and identical-
looking placebos for each were assessed. Medication
was distributed in a double-blind manner on the ba-
sis of order of appearance of the name of the volun-
teers in computer-generated randomization lists, and
distribution was stratified for the continent visited.
The volunteers received verbal and written instruc-
tions to the effect that they werenot to take any medi-
cation so long as they had no diarrhea, but they could
start self-treatment immediately after onset of symp-
toms. Diarrhea was defined as at least one watery
stool or a pasty stool when accompanied by concom-
itant symptoms, such as cramps, nausea, vomiting,
or fever. Unformed stools were defined as a com-
bination of watery and pasty stools. By allowing
treatment immediately upon onset of symptoms, we
again wanted to imitate the actual usage pattern.
Once initiated, self-treatment was to be continued
for 48 hours, or at least until the symptoms vanished.
Ifno improvement was observed after this time, the
volunteers were advised to see a local doctor.
Upon return, the volunteers were to immediately
send back a completed questionnaire and the remain-
ing test medication. Compliance was judged on the
basis of the questionnaire and on the pill count. Ef-
ficacy and adverse effects were evaluated according
to the questionnaire. Cure was defined as the disap-
pearance of all symptoms. No stool samples were
analyzed.
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Figure 3. Median number of un-
formed stools after BSSor loperamide
therapy in trial 2.
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during the trial period; an additional 17 were ex-
cluded because they gavecontradictory answers; and
nine were withdrawn from efficacy evaluation be-
cause they had adverse reactions and discontinued
medication. Thus, 530volunteers wereevaluated for
drug efficacy.
The travelers who were evaluated showed no sig-
nificant differences with respect to age, sex, desti-
nation, or travel style.Sincethe travelerswereallowed
duced by rv200/o the time until total relief from all
symptoms (P <.02). Figure 4 illustrates that the de-
crease in unformed stools passed was similar to that
in the other studies. At the end of the observation
period, diarrhea persisted significantly more often
in the placebo group. BSS relieved severe illness as
effectively as it relieved mild illness.
In trial 4, 380/0 of the study population of 2,098
(2,580 recruits; 482 drop-outs) suffered from diar-
rhea but only 654 (31 0/0) took their trial medication.
Of those who took their medication, rvl00/0 in each
of the self-treatment groups showed poor compli-
ance (n = 63) and had to be excluded on the basis
of either recorded intake of medication or the pill
count; 35of the volunteers took another medication
Table 2. Enteropathogensidentifiedin pretreatment stool
specimens.
Percentage of specimens
from indicated area
with pathogen
Pathogen West Africa Mexico
ETEC 42 24
EAEC 7 6
EIEC 0 2
Shigella species 7 6
Salmonella species 4 1
Campylobacter jejuni 1 2
Cryptosporidium 2 0
Aeromonas 0 1
Pseudomonas shigelloides 7 0
Entamoeba histolytica 2 0
Giardia lamblia 0 2
1.0
0.5
1.0 -""--
0.5
12
IWest Africa I
IMexico I
24 36 48
fZJ ass, 4.2g/day
o Placebo
* P<.05
60 72
NOTE. Among participants in West Africa, pathogens were iso-
lated in 79 (60%) of 132 specimens; in Mexico, 42 (38 %) of 112
specimens. ETEC = enterotoxigenic E. coli; EAEC = entero-
adherent E. coli; EIEC = enteroinvasive E. coli.
Hours after initiation of treatment
Figure 4. Median number of unformed stools after BSS
or placebo therapy in trial 3.
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Figure 5. Concomitant symptoms in
patients with diarrhea during the first
24 hours of treatment.
BDLMSTP BDLMSTP BDLMSTP BDLMSTP
Mean: 65.6% 45.7% 12.4% 18.0%
Figure 6. Proportion of patients cured by various ther-
apeutic agents within defined time periods in trial 4; (.) =
P < .0001 compared with other agents, (*) = P <.006
for any agent compared with placebo.
tioned above, the patients wereallowed to start treat-
ment immediately, and we are unable to ascertain
whether diarrhea was of the same severity in the var-
ious treatment groups. During the second day of
treatment, the patients in all treatment groups ex-
cept the SF 68 group had an average of 1.4-1.7 bowel
movements.
Patients with dysentery, defined here as the pres-
ence of feverand/or blood mixed with stools, showed
results different from those in patients with non-
dysenteric illness. All agents except for placebo and
SF 68 were effective in 80070-90070 of the nondysen-
-------BSS n.~
-- Doxycycine n. 62
•••••••••• Loperamide n • n
----- Mecilinam n • 53
_ .. _ •••- SF 68 n. 60
-._._.- TMP-SMZ n. 29
............. Placebo n • 75
48h
, .
24h
Duration of medication
t 4h 8h
Start of
medication
40
50
70
60
80
90
30
20
10
100
Proportionof patients
with diarrhea or other
remainingsymptoms
%
to start treatment immediately, it remains unknown
whether the participants in all treatment groups were
suffering from diarrhea of similar severity. However,
when the incidence of concomitant symptoms was
compared among the various treatment groups, no
significant differences were detected. The lower
proportion of symptoms in the BSS group (figure
5) may be explained by less severe disease, or BSS
may have prevented these symptoms more effectively
than other active agents during the first 24 hours of
treatment. These lower proportions just missed sig-
nificance according to the 'X}' test, which was applied
throughout the study.
The assessment of the time from initial medica-
tion until disappearance of symptoms showed sig-
nificant differences between the various agents
tested: slightly more than 40070 of those who took
loperamide were cured within 4 hours, making this
agent clearly the fastest-acting one (figure 6). After
8 and 24 hours, this lead was reduced, with BSS and
TMP-SMZ showing similar success rates. After 48
hours all active agents (except for SF 68, which never
showed any significant benefit) had cured f\J80OJo of
all patients. Similar success and failure rates were
observed in East and West Africa, Asia, and Latin
America.
Approximately 20070 of all patients remained sick
in each treatment group after 48 hours. Future
studies will have to determine the causes of the de-
lay in cure and the outcome in these patients.
The number of unformed stools possibly de-
creased most in the loperamide group during the first
24 hours of treatment (figure 7). However, as men-
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crobial agents, but it showed no tendency to increase
the proportion of participants with persistent dysen-
teric disease when compared with the proportion in
the placebo group. However, a longer follow-up
would be needed to judge this.
Analysis of the cure rate of the symptoms con-
comitant with diarrhea showed no significant differ-
ences with respect to vomiting or fever between par-
ticipants given active agents and those given placebo.
On the other hand, a systemic antimicrobial agent
and loperamide were superior in curing abdominal
cramps.
No serious adverse reactions occurred in any of
the four studies with any of the active agents. Black
tongue and black stools were reported, but these are
anticipated effects of BSS therapy. Tinnitus, consti-
pation, and other symptoms were not significantly
increased in any treatment group of any study de-
scribed.
Percentage of patients whose concomitant
symptoms were alleviated at indicated time
Table 3. Concomitant symptoms alleviated by therapy as
compared with placebo.
Figure 7. Averagenumber of unformed (watery or pasty)
stools in different treatment groups during various treat-
ment periods as compared with that in placebo group
(trial 4).
teric cases. In patients with dysenteric symptoms,
which accounted for 180/0 of all diarrheas, only an-
timicrobial agents showed similar rates. In view of
the small number of dysenteric cases, no significant
differences in outcome could be detected. Lopera-
mide may be less effective than systemic antimi-
Discussion and Conclusions
In all trials BSS was significantly superior to placebo
in several respects. It decreased stool frequency in
the total study population and in subsegments of spe-
cific etiology, including shigellosis. It increased the
proportion of patients relieved of symptoms within
the study period and reduced the time until total re-
lief. According to both studies in which BSS was
compared with loperamide, the latter exerted a faster
effect than BSS.
Taking four or eight doses of BSS within 4 hours
after initiation of treatment is not convenient if treat-
ment is begun late in the evening. Spacing out the
frequency of administration might lead to more con-
venience as well as to greater efficacy, as in the
prevention studies. As reported by Gryboski [9], a
therapeutic regimen of BSS every 3 hours has been
successfully tested in a pediatric population, but such
a regimen (or possibly a standard dosing of four
times daily) needs to be confirmed in adult patients
with travelers' diarrhea.
The toxicity of the agents described in this review
and those used in self-therapy for travelers' diarrhea
seems to be more a theoretical concern than of prac-
tical relevance. Although hundreds of volunteers in-
cluded in our various studies were invited to call us
collect from any place in the world in case of severe
adverse reactions, none ever did so, and no severe
adverse event was reported in the questionnaires. Ap-
parently, other researchers in this field have had simi-
time24-48hPretreatment 0-24h
Abdominal cramps
Nausea Vomiting "Fever"
Therapy 24h 48h 48h 48h 48h
BSS 51.4* 62.1 62.5 33.3 44.4
Doxycycline sz.it 81.0+ 80.6* 77.8 75.0
Loperamide 67.6+ 77.9+ 72.3 71.4 53.3
Mecillinam 66.7+ 81.4+ 81.8* 83.3 69.2
SF 68 48.0 67.4* 66.7 80.0 68.8
TMP-SMZ 67.7t 77.8* 80.0 50.0 77.8
Placebo 31.1 45.6 51.2 33.3 43.8
* P < .05.
t p < .01.
+P < .001.
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lar experiences. If the dosage and duration of treat-
ment as prescribed by the manufacturer is not
exceeded, BSS seems to be a safe agent [10]. Simi-
larly, loperamide is well tolerated, but two studies
indicated that in dysenteric cases illness may be
slightly aggravated [11, 12]. There is no indication
at all that this may be the case in nondysenteric
travelers' diarrhea, and to our knowledge no severe
adverse reactions- have been reported in treatment
of such cases with loperamide. Systemic antimicro-
bial agents above all have a known, significant inci-
dence of allergic reactions.
As shown by the most recent study (trial 4), diar-
rhea continues to bother more than one-third of
travelers to the tropics. Apparently, the etiology of
travelers'diarrhea is similar everywhere[13, 14]; con-
sequently, the same therapeutic regimen would ap-
ply everywhere.
When considering what to add to a travel kit for
treatment of travelers' diarrhea, or for self-therapy
after return home, the first choice is loperamide for
the more common nondysenteric diarrhea and sys-
temic antimicrobial agents for dysenteric cases. Al-
though it is less rapidly effective, BSS may be a sec-
ond choice that also has one definite advantage: it
is the agent that adults can take at the prescribed
eight dosages of 525 mg of BSS every half hour to
one hour for all types of travelers' diarrhea. Since
16 tablets of 262.5 mg or almost a quarter liter of
the liquid preparation will be needed every 24 hours,
a significant addition to the volume of luggage must
be considered if the traveler chooses to take BSS.
Steffen
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